Evidence map›Paper›PMID 30514404›Full record

ArticleJournal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale2018

Does metformin usage improve survival in head and neck squamous cell carcinoma? A population-based study.

Alexandra E Quimby, Nicole L Lebo, Rebecca Griffiths, Stephen Hall, Jim Dimitroulakos, Stephanie Johnson-Obaseki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alexandra E QuimbyDepartment of Otolaryngology, Head and Neck Surgery, University of Ottawa, 501 Smyth Rd, Module S - Room M2566, Box 216, Ottawa, ON, K1H 8L6, Canada. Aquim047@uottawa.ca.ORCID http://orcid.org/0000-0003-4864-8917
Nicole L LeboDepartment of Otolaryngology, Head and Neck Surgery, University of Ottawa, 501 Smyth Rd, Module S - Room M2566, Box 216, Ottawa, ON, K1H 8L6, Canada.
Rebecca GriffithsInstitute for Clinical and Evaluative Sciences, Queen's University, Abramsky Hall, Room 208, 21 Arch Street, Kingston, ON, K7L 3N6, Canada.
Stephen HallDepartment of Otolaryngology, Head and Neck Surgery, Queen's University, 18 Barrie Street, Kingston, ON, K7L 3N6, Canada.
Jim DimitroulakosOttawa Hospital Research Institute, 501 Smyth Rd, Box 511, Ottawa, ON, K1H 8L6, Canada.
Stephanie Johnson-ObasekiDepartment of Otolaryngology, Head and Neck Surgery, University of Ottawa, 501 Smyth Rd, Module S - Room M2566, Box 216, Ottawa, ON, K1H 8L6, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe sought to expand upon preliminary data suggesting that metformin confers a survival benefit to patients with head and neck squamous cell carcinoma (HNSCC).

methodsA large-scale retrospective cohort study of all patients in Ontario diagnosed with squamous cancer of the larynx, hypopharynx, and nasopharynx between Dec 1st 2007 to Dec 1st 2012 was undertaken. The Institute for Clinical and Evaluative Sciences was accessed to obtain patient demographic, treatment and outcome information. We included patients on metformin at the time of diagnosis. Kaplan Meier methods and Cox Regression models were used.

resultsPatients taking metformin at the time of diagnosis had a higher comorbid status but were otherwise similar to patients without metformin usage. Using multivariate analysis, neither overall survival nor disease specific survival was improved in patients on metformin (OS: HR 1.123, p = .338; DSS: HR 1.048, p = .792).

conclusionsNo survival advantage was observed in patients with HNSCC taking metformin at the time of diagnosis.

Indexed as

AgedAged, 80 and overComorbidityFemaleHumansHypoglycemic AgentsMaleMetforminRetrospective StudiesSquamous Cell Carcinoma of Head and NeckSurvival AnalysisTreatment OutcomeHypoglycemic AgentsMetforminHypopharynxLarynxMetforminNasopharynxSquamous cell carcinoma

Identifiers

PMID30514404
PMCPMC6278022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.